Navigation Links
Canadian researchers find potential new leukemia treatment with old antibiotic drug
Date:11/14/2011

(Toronto Nov. 14, 2011) Clinician-scientists in the Princess Margaret Cancer Program have found a promising approach to treating leukemia, using an old drug in a new way.

The proof-of-concept research published today in Cancer Cell (10.1016/j.ccr.2011.10.015) describes how the Canadian team discovered that the antibiotic tigecycline targets and destroys leukemia stem cells by cutting off the cell's energy production.

"If you think of all the cells in the body as a power grid, we've discovered that tigecycline can cause a power outage in leukemia stem cells, while still keeping the lights on in all the healthy cells," says Dr. Aaron Schimmer, clinician-scientist at the Campbell Family Institute for Cancer Research in the Princess Margaret Cancer Program, University Health Network. He is also an associate professor in the departments of medicine, medical biophysics, and Institute of Medical Science at the University of Toronto (U of T).

To identify known drugs with previously unrecognized ability to kill leukemia cells and leukemia stem cells, the scientific team amassed a library of hundreds of known drugs to try, including tigecycline an intravenous antibiotic normally used to treat skin and abdominal infections. A high-speed, pipette-handling robot tested varying doses of each drug to see if any affected leukemia cells.

"Technology made this discovery possible. In three days, we found which potential leukemia drugs might be hiding in plain sight," says Dr. Schimmer. "Sifting through every combination by hand would have taken months."

"We tested more than 500 existing drugs on leukemia. Of the handful that made an impact, tigecycline was the most potent and revealed novel insights into the biology of leukemia at a cellular level," says lead author, Marko krtić, an MD/PhD student in the Faculty of Medicine at U of T, completing his PhD studies in Dr. Schimmer's lab.

The Canadian team demonstrated that leukemia cells have unique energy requirements and it is possible to selectively shut down this energy production in leukemia cells by blocking protein synthesis in the mitochondria.

By looking for new treatments in approved drugs, cancer researchers may be able to rapidly test these new strategies in patients, says Dr. Schimmer, who is now beginning multi-centre clinical trials with tigecycline as a treatment for leukemia.


'/>"/>

Contact: Geoff Koehler
geoff.koehler@uhn.ca
416-340-4011
University Health Network
Source:Eurekalert

Related medicine news :

1. Heart transplant surgery safe and effective: A Canadian retrospective spanning 3 decades
2. Canadian Journal of Cardiology publishes report on delayed vs. immediate coronary stenting
3. How hemp got high: Canadian scientists map the cannabis genome
4. Fatal crashes in the US: Fewer Canadian drivers under the influence
5. Skin color matters when it comes to Canadians health: UBC study
6. Most Canadians can be uniquely identified from their date of birth and postal code
7. US physician practices spend 4 times Canadian practices
8. US physicians spend nearly 4 times more on health insurance costs than Canadian counterparts
9. New Canadian blood pressure education program a powerful tool in fight to reduce stroke
10. Medicare improved Canadian doctors salaries: Queens University study
11. Canadians should demand commitments for pharmacare program, says CMAJ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... , ... “The Trainer”: an electrifying and suspenseful gunslinger novel with a ... an active imagination and an enthusiasm for action and adventure stories. , ... Hart, who sat looking at the thirty-three notches that lined the edges of the ...
(Date:3/22/2017)... ... March 22, 2017 , ... Cosmetic Town, an online plastic ... its companion print magazine. The new magazine, scheduled for release in mid-April, includes ... by board-certified doctors from across the country. , According to the senior editor ...
(Date:3/22/2017)... ... 22, 2017 , ... The American Society for Preventive ... form for prescribers to improve patients’ access to the revolutionary therapy for appropriate ... part of the article entitled “PCSK9 Inhibitor Access Barriers: Issues and Recommendations: ...
(Date:3/22/2017)... ... March 22, 2017 , ... In recognition of Colon Cancer ... focused on cancer patients, cancer centers and advocacy groups, and MJH Studios™, a ... series, “No Ifs, Ands, or Butts,” that focuses on Colorectal Cancer detection, prevention ...
(Date:3/22/2017)... ... March 22, 2017 , ... An intensive search of the medical ... reports Leslie Norins, MD, PhD. He says investigating this possibility, is important ... virus and in new infections with HIV. , His findings appear on ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 2017 Serve You Rx Vermont, LLC, a wholly ... You), based in Milwaukee, Wisconsin , has ... in Middlebury, Vermont , from Pharmacy Health ... so it was perfect timing for this opportunity to present ... Serve You. "Like us, NEMOP has a high-touch service model, ...
(Date:3/22/2017)... , Mar 22, 2017 Research ... Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022" ... ... Inhibitors Market & Clinical Pipeline Insight 2022 report gives comprehensive ... and integration of immune check point inhibitors as main streamline ...
(Date:3/22/2017)... , March 22, 2017 ... Manufacturing Organization (CDMO), held a special event to introduce ... in Lexington, Kentucky . The inaugural ... Piramal Group Chairman Ajay Piramal, and Piramal Pharma ... ...
Breaking Medicine Technology: